Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
HYPRGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Preliminary, Unaudited Financial Results Preliminary, unaudited revenue for the fourth qua
Hyperfine, Inc. to Participate in Upcoming Investor Conferences
HYPRGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced their schedule for upcoming investor conferences. Hyperfine will discuss with investors recently announced milestones and growth catalysts, including its two major new technology clearances, commercial launch and market feedback
Hyperfine, Inc. Reports Second Quarter 2025 Financial Results
HYPRGUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update.
Hyperfine Announces Key Executive Appointments to Strengthen its Leadership Position in AI-Powered Portable MRI
HYPRGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine appoints Rob Fasciano, PhD, and Rafael O’Halloran, PhD, to help advance AI-powered MRI technology and scale next-gen imaging solutions.
Hyperfine Stock Is Soaring Higher Monday: What's Going On?
HYPRHyperfine announced it secured clearance from the FDA for its new Swoop system.
Hyperfine Secures FDA Clearance For Next-Gen AI-Powered Portable MRI Scanner
HYPRHyperfine Announces FDA Clearance Of Optive AI Software For Its Swoop system
HYPRB. Riley Securities Maintains Buy on Hyperfine, Lowers Price Target to $1
HYPRHyperfine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
HYPRWells Fargo Maintains Equal-Weight on Hyperfine, Lowers Price Target to $0.68
HYPRHyperfine Lowers FY2025 Sales Guidance from $15.47M-$16.76M to $14.18M-$15.47M vs $15.67M Est
HYPRHyperfine Q1 EPS $(0.12), Inline, Sales $2.14M Miss $2.81M Estimate
HYPRHyperfine Enrolls Initial Patients In NEURO PMR Study
HYPRLake Street Initiates Coverage On Hyperfine with Buy Rating, Announces Price Target of $1.5
HYPRB. Riley Securities Maintains Buy on Hyperfine, Lowers Price Target to $1.2
HYPRWells Fargo Maintains Equal-Weight on Hyperfine, Raises Price Target to $1.29
HYPRHyperfine Expects Revenue For The First Half Of 2025 To Be ~$6M; Expects Annual Revenue Growth For The Full Year 2025 To Be 20% To 30% Over 2024; Expects Cash Burn For The FY25 To Be ~$25M-$27M, Representing A 32% Decline At The Midpoint As Compared To 20
HYPRHyperfine Q4 EPS $(0.14), Inline, Sales $2.32M Miss $3.00M Estimate
HYPRHyperfine, Nvidia Partner To Make Brain MRIs More Affordable
HYPRThe partnership integrates NVIDIA's AI expertise with Hyperfine's Swoop® system, the first FDA-approved portable MRI, aiming to make brain MRIs faster, smarter and more affordable.
Hyperfine Announces Collaboration With NVIDIA, Focused On AI-Powered Image Reconstruction And Embedding Clinical Decision Support Into MRI Workflow
HYPRHyperfine Announces 10 Abstracts At RSNA, Highlighting The Expanding Utility And Potential Of Portable MR Brain Imaging In Diverse Clinical And Research Settings
HYPRHyperfine Unveils Alzheimer's Research At CTAD Conference, Showcasing Swoop System's Advanced Imaging Data And Quality In Monitoring Amyloid-Related Imaging Abnormalities
HYPR